Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class Il-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
Type:
Application
Filed:
August 29, 2023
Publication date:
August 8, 2024
Applicant:
Selecta Biosciences, Inc.
Inventors:
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
Type:
Application
Filed:
June 6, 2023
Publication date:
May 16, 2024
Applicant:
Selecta Biosciences, Inc.
Inventors:
Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist, an anti-IgM agent and immunosuppressant (e.g., synthetic nanocarriers comprising immunosuppressant) in combination. The methods and compositions provided can be used for modulating an immune response to an antigen, such as by enhancing regulatory T cells, such as antigen-specific regulatory T cells.
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.
Type:
Application
Filed:
December 8, 2022
Publication date:
October 12, 2023
Applicant:
Selecta Biosciences, Inc.
Inventors:
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
Type:
Application
Filed:
March 2, 2023
Publication date:
October 12, 2023
Applicant:
Selecta Biosciences, Inc.
Inventors:
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
Type:
Grant
Filed:
March 4, 2016
Date of Patent:
October 10, 2023
Assignee:
Selecta Biosciences, Inc.
Inventors:
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
Type:
Application
Filed:
December 9, 2022
Publication date:
October 5, 2023
Applicant:
Selecta Biosciences, Inc.
Inventors:
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
Type:
Grant
Filed:
February 22, 2016
Date of Patent:
August 8, 2023
Assignee:
Selecta Biosciences, Inc.
Inventors:
Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
Type:
Application
Filed:
December 16, 2021
Publication date:
November 10, 2022
Applicant:
Selecta Biosciences, Inc.
Inventors:
David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including antigen-specific regulatory T cells.
Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.